Cosmos Health Reports FY24 Revenue $54.34M Up From $53.38M YoY

Benzinga
04-17

Full Year 2024 Financial Highlights

Income Statement:

FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gains recognized in the prior year.

  • Revenue increased by 2.0% to $54.43 million in FY 2024, from $53.38 million in the prior year, driven primarily by sustained organic growth and continued contributions from prior acquisitions.
  • Gross margin was 7.92%, compared to 8.15% in FY 2023, reflecting a greater mix of revenue from the lower-margin logistics distribution segment.
  • Total operating expenses declined by 24.16% to $19.86 million, compared to $26.18 million in FY 2023. This includes:
    • 40.26% reduction in general and administrative expenses.
    • 71% decrease in sales and marketing expenses, following a strategic reduction in promotional spend.
  • Total other income, net, was a loss of $0.64 million in FY 2024, compared to income of $3.29 million in FY 2023. The year-over-year decline was primarily due to the absence of non-cash gains recognized in the prior year, including:
    • $1.91 million gain on debt extinguishment.
    • $1.44 million bargain purchase gain related to the acquisition of Cana Laboratories.
  • Adjusted EBITDA was negative $3.73 million, compared to positive $0.06 million in FY 2023, while Adjusted net loss widened to $4.74 million from $0.81 million.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10